GlassScriptPhysician profile
Joseph A Koon
NPI 1922687649
$1,666.00
in general payments reported to CMS, 2019-2025
26 companies · $1,174 in 2025
The $1,174 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $492 · 2025: $1,174.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,666.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,666.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $249.91 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $232.93 | 2024-2025 | Rexulti |
| Abbvie INC. | $142.44 | 2024-2025 | |
| Dexcom, INC. | $126.98 | 2024-2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $104.85 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $98.58 | 2024-2025 | Jardiance |
| Exact Sciences Corporation | $90.41 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astrazeneca Pharmaceuticals LP | $88.62 | 2024-2025 | Breztri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $84.13 | 2024-2025 | Xifaxan |
| Lundbeck LLC | $53.41 | 2024-2025 | Rexulti |
| Amgen INC. | $45.91 | 2024-2025 | Otezla, Repatha, Otezla |
| Antares Pharma, INC. | $43.84 | 2025 | Xyosted |
| Takeda Pharmaceuticals U.S.A., INC. | $37.45 | 2024-2025 | Trintellix |
| Glaxosmithkline, LLC. | $30.55 | 2024 | Arexvy |
| Lilly USA, LLC | $29.14 | 2024-2025 | Zepbound, Mounjaro |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $27.05 | 2025 | Caplyta |
| Merck Sharp & Dohme LLC | $25.12 | 2025 | Gardasil 9, Capvaxive |
| Tris Pharma INC | $22.65 | 2025 | Dyanavel Xr |
| Sanofi-Aventis U.S. LLC | $21.80 | 2025 | |
| Baxter Healthcare | $16.64 | 2024 | Hillrom - Monarch Airway Clearance System |
| Mylan Specialty L.P. | $16.40 | 2024 | Yupelri |
| Phathom Pharmaceuticals, INC. | $16.33 | 2025 | Voquezna |
| Globus Medical, INC. | $15.83 | 2025 | Senza |
| Nevro Corp. | $15.67 | 2024 | Senza |
| Viatris Specialty LLC | $15.52 | 2025 | Yupelri |
| Axsome Therapeutics, INC. | $13.84 | 2025 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Koon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.